Transmedics Group Inc (TMDX)

$124.1

-2.5

(-1.97%)▲

Live

Performance

  • $121.91
    $127.98
    $124.10
    downward going graph

    1.76%

    Downside

    Day's Volatility :4.74%

    Upside

    3.03%

    downward going graph
  • $36.42
    $177.37
    $124.10
    downward going graph

    70.65%

    Downside

    52 Weeks Volatility :79.47%

    Upside

    30.03%

    downward going graph

Returns

PeriodTransmedics Group IncSector (Health Care)Index (Russel 2000)
3 Months
-15.13%
3.6%
0.0%
6 Months
46.34%
10.2%
0.0%
1 Year
206.46%
19.6%
0.0%
3 Years
348.62%
16.8%
-23.0%

Highlights

Market Capitalization
4.2B
Book Value
$5.70
Earnings Per Share (EPS)
0.04
PE Ratio
3178.75
Wall Street Target Price
183.0
Profit Margin
0.84%
Operating Margin TTM
10.94%
Return On Assets TTM
2.45%
Return On Equity TTM
1.79%
Revenue TTM
358.8M
Revenue Per Share TTM
10.94
Quarterly Revenue Growth YOY
117.9%
Gross Profit TTM
65.3M
EBITDA
42.8M
Diluted Eps TTM
0.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.26
EPS Estimate Next Year
1.91
EPS Estimate Current Quarter
0.21
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Transmedics Group Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 47.46%

Current $124.10
Target $183.00

Company Financials

FY18Y/Y Change
Revenue
13.0M
↑ 69.38%
Net Income
-23.8M
↑ 14.09%
Net Profit Margin
-182.5%
↑ 88.46%
FY19Y/Y Change
Revenue
23.6M
↑ 81.33%
Net Income
-33.5M
↑ 41.21%
Net Profit Margin
-142.12%
↑ 40.38%
FY20Y/Y Change
Revenue
25.6M
↑ 8.62%
Net Income
-28.7M
↓ 14.31%
Net Profit Margin
-112.13%
↑ 29.99%
FY21Y/Y Change
Revenue
30.3M
↑ 18.03%
Net Income
-44.2M
↑ 53.8%
Net Profit Margin
-146.11%
↓ 33.98%
FY22Y/Y Change
Revenue
93.5M
↑ 208.83%
Net Income
-36.2M
↓ 18.06%
Net Profit Margin
-38.77%
↑ 107.34%
FY23Y/Y Change
Revenue
241.6M
↑ 158.53%
Net Income
-25.0M
↓ 30.92%
Net Profit Margin
-10.36%
↑ 28.41%
Q1 FY23Q/Q Change
Revenue
41.6M
↑ 32.44%
Net Income
-2.6M
↓ 60.77%
Net Profit Margin
-6.34%
↑ 15.08%
Q2 FY23Q/Q Change
Revenue
52.5M
↑ 26.26%
Net Income
-1.0M
↓ 62.03%
Net Profit Margin
-1.91%
↑ 4.43%
Q3 FY23Q/Q Change
Revenue
66.4M
↑ 26.62%
Net Income
-25.4M
↑ 2439.66%
Net Profit Margin
-38.27%
↓ 36.36%
Q4 FY23Q/Q Change
Revenue
81.2M
↑ 22.19%
Net Income
4.0M
↓ 115.86%
Net Profit Margin
4.97%
↑ 43.24%
Q1 FY24Q/Q Change
Revenue
96.9M
↑ 19.31%
Net Income
12.2M
↑ 202.58%
Net Profit Margin
12.59%
↑ 7.62%
Q2 FY24Q/Q Change
Revenue
114.3M
↑ 18.02%
Net Income
12.2M
↓ 0.02%
Net Profit Margin
10.67%
↓ 1.92%
FY18Y/Y Change
Total Assets
42.2M
↑ 13.93%
Total Liabilities
47.0M
↓ 77.16%
FY19Y/Y Change
Total Assets
105.3M
↑ 149.78%
Total Liabilities
50.7M
↑ 7.81%
FY20Y/Y Change
Total Assets
152.0M
↑ 44.38%
Total Liabilities
48.1M
↓ 4.97%
FY21Y/Y Change
Total Assets
134.9M
↓ 11.27%
Total Liabilities
67.0M
↑ 39.27%
FY22Y/Y Change
Total Assets
277.1M
↑ 105.46%
Total Liabilities
89.8M
↑ 33.91%
FY23Y/Y Change
Total Assets
706.0M
↑ 154.76%
Total Liabilities
568.8M
↑ 533.66%
Q1 FY23Q/Q Change
Total Assets
287.1M
↑ 3.59%
Total Liabilities
94.5M
↑ 5.23%
Q2 FY23Q/Q Change
Total Assets
690.4M
↑ 140.47%
Total Liabilities
545.1M
↑ 477.1%
Q3 FY23Q/Q Change
Total Assets
689.2M
↓ 0.16%
Total Liabilities
562.8M
↑ 3.23%
Q4 FY23Q/Q Change
Total Assets
706.0M
↑ 2.44%
Total Liabilities
568.8M
↑ 1.08%
Q1 FY24Q/Q Change
Total Assets
723.8M
↑ 2.52%
Total Liabilities
564.4M
↓ 0.79%
Q2 FY24Q/Q Change
Total Assets
758.6M
↑ 4.8%
Total Liabilities
568.7M
↑ 0.77%
FY18Y/Y Change
Operating Cash Flow
-26.0M
↑ 12.49%
Investing Cash Flow
12.3M
↓ 50.49%
Financing Cash Flow
22.1M
↑ 735366.67%
FY19Y/Y Change
Operating Cash Flow
-32.3M
↑ 24.25%
Investing Cash Flow
-60.5M
↓ 591.6%
Financing Cash Flow
92.7M
↑ 320.25%
FY20Y/Y Change
Operating Cash Flow
-30.3M
↓ 6.26%
Investing Cash Flow
-41.6M
↓ 31.24%
Financing Cash Flow
75.5M
↓ 18.52%
FY21Y/Y Change
Operating Cash Flow
-28.9M
↓ 4.63%
Investing Cash Flow
29.3M
↓ 170.36%
Financing Cash Flow
1.4M
↓ 98.16%
FY22Y/Y Change
Operating Cash Flow
-45.8M
↑ 58.73%
Investing Cash Flow
54.5M
↑ 86.26%
Financing Cash Flow
167.9M
↑ 11955.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.7M
↑ 114.65%
Investing Cash Flow
-927.0K
↓ 66.46%
Financing Cash Flow
4.0M
↑ 29.14%

Technicals Summary

Sell

Neutral

Buy

Transmedics Group Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Transmedics Group Inc
Transmedics Group Inc
-20.63%
46.34%
206.46%
348.62%
614.04%
Stryker Corporation
Stryker Corporation
0.83%
12.78%
40.21%
33.69%
71.83%
Boston Scientific Corp.
Boston Scientific Corp.
4.85%
29.48%
75.68%
96.28%
127.87%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.32%
-19.19%
1.77%
-39.29%
-7.22%
Abbott Laboratories
Abbott Laboratories
3.99%
11.51%
24.65%
-4.53%
46.22%
Medtronic Plc
Medtronic Plc
2.65%
14.48%
27.42%
-24.18%
-13.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Transmedics Group Inc
Transmedics Group Inc
3178.75
3178.75
NA
1.26
0.02
0.02
NA
5.7
Stryker Corporation
Stryker Corporation
40.15
40.15
2.64
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
70.26
70.26
2.14
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.67
27.67
3.65
2.6
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.83
35.83
4.31
4.67
0.14
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
30.23
30.23
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Transmedics Group Inc
Transmedics Group Inc
Buy
$4.2B
614.04%
3178.75
0.84%
Stryker Corporation
Stryker Corporation
Buy
$137.1B
71.83%
40.15
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$127.3B
127.87%
70.26
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.3B
-7.22%
27.67
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$205.1B
46.22%
35.83
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.2B
-13.49%
30.23
12.06%

Insights on Transmedics Group Inc

  • Increasing Revenue

    Revenue is up for the last 12 quarters, 5.37M → 114.30M (in $), with an average increase of 23.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 12.19M → 12.19M (in $), with an average decrease of 0.0% per quarter

Institutional Holdings

  • FMR Inc

    13.48%

  • BlackRock Inc

    7.94%

  • Vanguard Group Inc

    7.58%

  • Driehaus Capital Management LLC

    4.46%

  • Amvescap Plc.

    4.09%

  • Eventide Asset Management, LLC

    3.44%

Company Information

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.

Organization
Transmedics Group Inc
Employees
584
CEO
Dr. Waleed H. Hassanein M.D.
Industry
Medical Specialties

Discover More

FAQs